Unibest
← Back to patent-cliff list

CAS 134-20-3

methyl 2-aminobenzoateMethyl anthranilate

Codes: IVAC-028, CAND-024, Ambroxol- 019

Application context (from source-drug indications)

Cystic fibrosisIvacaftorChronic bronchitisIvacaftorChronic obstructive pulmonary diseaseIvacaftorSinusitisIvacaftorHypertensionAmlodipine Besylate/Candesartan CilexetilChronic bronchitisRoxithromycin/Ambroxol HydrochlorideBronchitisRoxithromycin/Ambroxol HydrochlorideRespiratory tract infectionRoxithromycin/Ambroxol HydrochloridePneumoniaRoxithromycin/Ambroxol HydrochlorideTracheitisRoxithromycin/Ambroxol HydrochlorideBacterial infectionRoxithromycin/Ambroxol HydrochlorideHypertensionCandesartan CilexetilHeart failureCandesartan CilexetilEssential hypertensionCandesartan CilexetilMigraineCandesartan CilexetilCOVID-19Candesartan CilexetilManiaCandesartan CilexetilAnaesthesiaAmbroxol HydrochloridePharyngitisAmbroxol HydrochlorideRespiratory diseaseAmbroxol HydrochlorideBronchitisAmbroxol HydrochlorideParkinson's diseaseAmbroxol HydrochlorideParkinsonismAmbroxol Hydrochloride

Source drugs (routes using this intermediate)

DrugTierExpiry
IvacaftorTier B — Position early-
Amlodipine Besylate/Candesartan CilexetilTier C — Watch / trade-
Roxithromycin/Ambroxol HydrochlorideTier C — Watch / trade-
Candesartan CilexetilTier B — Position early-
Ambroxol HydrochlorideTier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.